Is There a Dose-Response Relationship? Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration | Zendy

Reut Shor | Zendy; Adiel Barak | Zendy; Anat Loewenstein | Zendy; Marganit Shahar-Gonen | Zendy; Michaella Goldstein | Zendy; Ronni Gamzu | Zendy; Dinah Zur | Zendy

Open Access

Is There a Dose-Response Relationship? Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration

Author(s) -

Reut Shor,

Adiel Barak,

Anat Loewenstein,

Marganit Shahar-Gonen,

Michaella Goldstein,

Ronni Gamzu,

Dinah Zur

Publication year - 2022

Publication title -

ophthalmologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.639

H-Index - 60

eISSN - 1423-0267

pISSN - 0030-3755

DOI - 10.1159/000525653

Subject(s) - medicine , bevacizumab , macular degeneration , choroidal neovascularization , group b , gastroenterology , ophthalmology , chemotherapy

The aim of study was to explore the dose-response relationship of anti-vascular endothelial growth factor (VEGF) agents, with bevacizumab as 1st-line treatment, on the visual-acuity (VA) outcome during the first year of treatment in neovascular AMD (nAMD) patients in real-life conditions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research